SCHEMBL28845273

SCHEMBL28845273

[CH2]CCNc1cc(Cl)nc(N)n1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.70
CYP2C19 P33261 1/20 0.70
HRH4 Q9H3N8 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 1/20 0.57
KMT2A Q03164 2/20 0.45
POLA1 P09884 1/20 0.45
TLR8 Q9NR97 2/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38
HSP90AB1 P08238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8597545 0.82 CYP2D6 (0.70) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL17315544 0.82 CYP2D6 (0.70) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL8053292 0.82 CYP2D6 (1.00) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL8049480 0.81 CYP2D6 (0.97) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL28265778 0.81 CYP2D6 (0.68) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL8600881 0.79 TLR8 (0.69) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL8055803 0.79 CYP2D6 (0.81) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL3209288 0.78 CYP2D6 (0.64) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL11752857 0.78 CYP2D6 (0.64) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1
SCHEMBL29750608 0.78 CYP2D6 (0.64) CYP2D6CYP2C19HRH4SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106794181-A MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions 托马斯·黑勒戴药物研究基金会 2017-05-31 CN disclosed